PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) will report its fourth quarter and full-year 2023 financial results and operational highlights on February 14, 2024. The Company aims to improve surgical outcomes and will host a conference call and webcast to discuss the results and provide an update on business operations.

PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

Date:	Wednesday, February 14, 2024
Time:	8:30 AM Eastern Time
Conference Call:	https://register.vevent.com/register/BI8900a42f492b4240a3bba8285558d15f
Webcast:	https://edge.media-server.com/mmc/p/7iigty2s

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Contacts: 

PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
Britchie@lifesciadvisors.com

When will PolyPid report its fourth quarter and full-year 2023 financial results?

PolyPid will report its fourth quarter and full-year 2023 financial results on February 14, 2024.

What is the ticker symbol for PolyPid?

The ticker symbol for PolyPid is PYPD.

What is the focus of PolyPid as a company?

PolyPid is a late-stage biopharma company aiming to improve surgical outcomes.

When will the conference call and webcast to discuss the financial results take place?

The conference call and webcast to discuss the financial results will take place on Wednesday, February 14, 2024, at 8:30 AM Eastern Time.